Vital Images showcased new enhancements to its Vitrea 4.0 and VitalConnect 4.1 software as well as the debut of Vital EP, a new electrophysiology planning application, during the 2007 Radiological Society of North America (RSNA) conference in Chicago last month.
Enhancements to the company’s Vitrea 4.0 workstation-client release include cardiovascular workflow improvements such as automatic segmentation and probing of the coronary tree, easier vessel management and labeling, centerline editing and comprehensive reporting with automatic population of findings.
Neurovascular improvements include motion correction and simultaneous multi-slice computation for 4D perfusion for stroke patients. The 4.0 release also includes improved colon enhancements such as fly-through capabilities, polyp probe and automatic registration of prone and supine. Among other usability improvements are computer-aided detection (CAD) designed to identify suspicious regions in the colon.
The company’s web-client enhancements in the VitalConnect 4.1 release include new cardiovascular tools, including automatic segmentation of the coronary tree, centerline editing and automatic stenosis calculation all designed to increase efficiency and productivity. Additional features include improved 2D performance and integrated reporting features. The combined workstation and web-client solution enables a streamlined workflow designed to improve efficiency, according to Vital Images.
The new EP planning application, Vital EP, contains a 3D advanced visualization and modeling tool for the EP lab. VitaL EP automatically segments out the pulmonary veins and creates a 3D anatomic model of the heart for superimposed EP mapping. In addition to its clinical features, Vital EP automatically exports a 3D model for display on the St. Jude Medical EnSite system, which is used to facilitate therapy for the treatment of arrhythmias.
The firm also demonstrated Medicsight ColonCAD, designed to automatically identify suspect regions in the colon, which is available in Europe with Vitrea 4.0, and will be available in the United States, pending FDA clearance, the company said.